Biodesix Inc (BDSX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Biodesix Inc stock (BDSX) is currently trading at $15.54. Biodesix Inc PS ratio (Price-to-Sales) is 1.66. Analyst consensus price target for BDSX is $30.00. WallStSmart rates BDSX as Sell.
- BDSX PE ratio analysis and historical PE chart
- BDSX PS ratio (Price-to-Sales) history and trend
- BDSX intrinsic value — DCF, Graham Number, EPV models
- BDSX stock price prediction 2025 2026 2027 2028 2029 2030
- BDSX fair value vs current price
- BDSX insider transactions and insider buying
- Is BDSX undervalued or overvalued?
- Biodesix Inc financial analysis — revenue, earnings, cash flow
- BDSX Piotroski F-Score and Altman Z-Score
- BDSX analyst price target and Smart Rating
Biodesix Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Biodesix Inc (BDSX) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, revenue growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Biodesix Inc (BDSX) Key Strengths (2)
Revenue surging 40.80% year-over-year
Paying $1.66 for every $1 of annual revenue
Supporting Valuation Data
Biodesix Inc (BDSX) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very expensive at 44.6x book value
Micro-cap company with very limited liquidity and high volatility
Low institutional interest, mostly retail-driven
Biodesix Inc (BDSX) Detailed Analysis Report
Overall Assessment
This company scores 28/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 2 register as strengths (avg 9.0/10) while 6 fall into concern territory (avg 1.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Price/Sales. Valuation metrics including Price/Sales (1.66) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 40.80%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Book (44.57) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -383.10%, Operating Margin at -6.84%, Profit Margin at -39.90%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -383.10% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 40.80% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
BDSX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
BDSX's Price-to-Sales ratio of 1.66x trades 84% above its historical average of 0.9x (81th percentile), historically expensive. The current valuation is 70% below its historical high of 5.49x set in Nov 2020, and 5423% above its historical low of 0.03x in Jun 2025. Over the past 12 months, the PS ratio has expanded from ~0.1x, reflecting growing market expectations outpacing revenue growth.
Compare BDSX with Competitors
Top DIAGNOSTICS & RESEARCH stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Biodesix Inc (BDSX) · HEALTHCARE › DIAGNOSTICS & RESEARCH
The Big Picture
Biodesix Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 88M with 41% growth year-over-year. The company is currently unprofitable, posting a -39.9% profit margin.
Key Findings
Revenue growing at 41% YoY, reaching 88M. This pace significantly outperforms most DIAGNOSTICS & RESEARCH peers.
Generating 629,000 in free cash flow and 778,000 in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -39.9% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Growth sustainability: can Biodesix Inc maintain 41%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor DIAGNOSTICS & RESEARCH industry trends, competitive moves, and regulatory changes that could impact Biodesix Inc.
Bottom Line
Biodesix Inc is a high-conviction growth story with revenue accelerating at 41% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -39.9% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(72 last 3 months)
| Insider | Type | Shares |
|---|---|---|
SCHULER, JACK W 10% Owner, Emeritus Director | Buy | +20,000 |
| Insider | Type | Shares |
|---|---|---|
SCHULER, JACK W 10% Owner, Emeritus Director | Buy | +80,000 |
| Insider | Type | Shares |
|---|---|---|
SCHULER, JACK W 10% Owner, Emeritus Director | Buy | +82,465 |
Data sourced from SEC Form 4 filings
Last updated: 8:26:08 AM
About Biodesix Inc(BDSX)
NASDAQ
HEALTHCARE
DIAGNOSTICS & RESEARCH
USA
Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company is headquartered in Boulder, Colorado.